ARTICLE | Clinical News
SAIK-MS:Phase I trial update
February 22, 2000 8:00 AM UTC
Active Biotech AB (SSE:ACTI B), Lund, Sweden Product: SAIK-MS Business: Autoimmune/Inflammation Therapeutic category: Immune modulation Target: Immune cells Description: Oral immune modulating SAIK c...